RNA-Based Therapeutics
This report catalogs 252 early-stage companies developing RNA-based therapeutics or enabling RNA drug discovery and delivery across seven distinct modalities.
Jeff Martin
The Future of AI Drug Discovery
221 early-stage companies using AI/ML to discover and design therapeutics — powered by HOUSTON intelligence.
TRIANA Biomedicines
Rational molecular glue degrader platform targeting undruggable oncology targets, with lead ALK fusion degrader in Phase 1/2 for NSCLC.
Commit Biologics
Bispecific complement engagers recruiting the innate immune system for B-cell depletion in autoimmune disease and cancer.
Neutrolis
Neutrolis is developing the first therapy designed to degrade neutrophil extracellular traps — attacking one of the root causes of autoimmunity without immunosuppression.
AvenCell Therapeutics
AvenCell just dosed the first patient with a CRISPR-engineered allogeneic CAR-T that simultaneously targets CD19 and CD20 — with a built-in switchable receptor that lets you retarget the same cells post-infusion.
Alltrna
Alltrna just put the first engineered tRNA therapeutic into a human trial, creating an entirely new drug class to address them.
One Bought a Podcast. The Other Bought a Lab.
Anthropic dropped $400M on a 9-person biotech AI startup. The same day, OpenAI bought a podcast. That tells you everything.
Seaport Therapeutics Shows 6.8x Bioavailability Boost With Anxiety Drug Prodrug
GlyphAgo took a European antidepressant the FDA rejected over liver toxicity — and may have solved both problems at once.
CanWell Pharma Gets FDA Nod for Dual-Payload ADC Aimed at Resistant HER2 Tumors
CAN016 carries two payloads in one antibody — designed specifically for patients who already failed ADC-based therapies.